中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
3期
293-294
,共2页
螺杆菌,幽门%新四联疗法%三联疗法%14C尿素呼气试验%转阴率
螺桿菌,幽門%新四聯療法%三聯療法%14C尿素呼氣試驗%轉陰率
라간균,유문%신사련요법%삼련요법%14C뇨소호기시험%전음솔
Helicobacter pylori%New quadruple chemotherapy%Traditional triple therapy%14C-urea breath test%Positive to nategive rate
目的 比较新四联疗法与传统三联疗法治疗幽门螺杆菌(Hp)的疗效.方法 选取120例14C尿素呼气试验(14C-UBT)阳性的消化性溃疡患者完全随机分为2组:治疗组采用奥美拉唑+铋剂+四环素+替硝唑治疗;对照组予奥美拉唑+克拉霉素+阿莫西林治疗.疗程结束后1周内做电子胃镜、组织学活检和14C-UBT.结果 治疗组对首次治疗患者14C-UBT转阴率为95.1%,再次治疗患者14C-UBT转阴率为89.5%,总14C-UBT转阴率为93.3%;而对照组分别为77.5%、55.0%和70.0%;治疗组溃疡愈合率为86.7%,对照组为71.7%.治疗组的首次、再次及总14C-UBT转阴率和溃疡愈合率均高于对照组(P＜0.05).结论 新四联疗法治疗Hp的14C-UBT转阴率及溃疡愈合率较传统三联疗法高,适合在临床推广.
目的 比較新四聯療法與傳統三聯療法治療幽門螺桿菌(Hp)的療效.方法 選取120例14C尿素呼氣試驗(14C-UBT)暘性的消化性潰瘍患者完全隨機分為2組:治療組採用奧美拉唑+鉍劑+四環素+替硝唑治療;對照組予奧美拉唑+剋拉黴素+阿莫西林治療.療程結束後1週內做電子胃鏡、組織學活檢和14C-UBT.結果 治療組對首次治療患者14C-UBT轉陰率為95.1%,再次治療患者14C-UBT轉陰率為89.5%,總14C-UBT轉陰率為93.3%;而對照組分彆為77.5%、55.0%和70.0%;治療組潰瘍愈閤率為86.7%,對照組為71.7%.治療組的首次、再次及總14C-UBT轉陰率和潰瘍愈閤率均高于對照組(P＜0.05).結論 新四聯療法治療Hp的14C-UBT轉陰率及潰瘍愈閤率較傳統三聯療法高,適閤在臨床推廣.
목적 비교신사련요법여전통삼련요법치료유문라간균(Hp)적료효.방법 선취120례14C뇨소호기시험(14C-UBT)양성적소화성궤양환자완전수궤분위2조:치료조채용오미랍서+필제+사배소+체초서치료;대조조여오미랍서+극랍매소+아막서림치료.료정결속후1주내주전자위경、조직학활검화14C-UBT.결과 치료조대수차치료환자14C-UBT전음솔위95.1%,재차치료환자14C-UBT전음솔위89.5%,총14C-UBT전음솔위93.3%;이대조조분별위77.5%、55.0%화70.0%;치료조궤양유합솔위86.7%,대조조위71.7%.치료조적수차、재차급총14C-UBT전음솔화궤양유합솔균고우대조조(P＜0.05).결론 신사련요법치료Hp적14C-UBT전음솔급궤양유합솔교전통삼련요법고,괄합재림상추엄.
Objective To compare the effect of new quadruple chemotherapy and traditional triple therapy for helicobacter pylori. Methods Totally 120 ulcer patients which being detected positive on 14C-Urea Breath Test (14C-UBT) are divided into 2 groups. The patients of treatment group were treated by omeprazole + bismuth +acheomycin + tinidazole and the control groups were treated with omeprazole + clarithromycin + amoxicillin. The patients of two groups were all made electronic gastroscope, histology and 14C-Urea Breath Test within 1 week after the course of treatment has ended. Results The positive-nategive rate on 14C-UBT of first time treated patients is 95.1%, the repeated treated patients was 89.5% and the total positive-nategive rate was 93. 3% on 14C-UBT in the treatment group, while the positive-nategive rate on 14C-UBT was 77.5%, 55.0% and 70.0% in the control group. The ulcer recovery rate in the patients of treatment group was 86.7% while control group was 71.7%. The ulcer recovery rate and the positive-nategive rate on 14C-UBT of first time treated, repeated treated and the total in the patients of treatment group were higher than the control group all (P ＜ 0.05). Conclusions The positive-nategive rate on 14C-UBT and the ulcer recovery rate of new quadruple chemotherapy are higher than that of traditional triple therapy.
